Expert: Dextromethorphan acts as uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist, modulating glutamatergic neurotransmission. Quinidine inhibits CYP2D6, increasing dextromethorphan bioavailability ~20-fold to achieve therapeutic CNS exposure.
Everyday: Calms down overexcited brain circuits that cause involuntary laughing or crying by blocking a glutamate receptor (NMDA) and activating a stabilizing receptor (sigma-1). Combined with a metabolism-slowing partner drug to keep levels high enough in the brain.
Targets: []